Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04302454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Dec 1, 2024 to Oct 21, 2027Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 1, 2024 to Dec 1, 2027 · Site details revised at 13 of 13 sitesv7Show 3 more changesShow less
Trial status: Recruiting to Active, Not Recruiting
Completion date: Dec 1, 2024 to Dec 1, 2027
Site details revised at 13 of 13 sites
NotablePrimary and study completion dates: Dec 1, 2022 to Dec 1, 2024Site details revised at 1 of 13 sitesv6Show 1 more changeShow less
Site details revised at 1 of 13 sites
MinorStart date: Mar 1, 2020 to Mar 19, 2020Site details revised at 2 of 13 sitesv5Show 1 more changeShow less
Site details revised at 2 of 13 sites
MinorSite details revised at 6 of 13 sitesv4
MinorStudy sites: 1 to 13v3
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1 · Interventions: Leuproreline (Drug), Radiotherapy (Radiation) to Leuprorelin (Drug), Radiotherapy (Radiation) · Collaborators expanded, about 3 wordsv2Show 3 more changesShow less
Study sites: 0 to 1
Interventions: Leuproreline (Drug), Radiotherapy (Radiation) to Leuprorelin (Drug), Radiotherapy (Radiation)
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aim of this project is to test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.